Therapeutic Potential of Polyphenols in Cardiac Fibrosis
Cardiac fibrosis, in response to injury and stress, is central to a broad constellation of cardiovascular diseases. Fibrosis decreases myocardial wall compliance due to extracellular matrix (ECM) accumulation, leading to impaired systolic and diastolic function and causing arrhythmogenesis. Although...
Main Authors: | Ning Zhang, Wen-Ying Wei, Ling-Li Li, Can Hu, Qi-Zhu Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2018.00122/full |
Similar Items
-
Editorial: Cardiac Fibrosis, From Lineage Tracing to Therapeutic Application
by: Claudio de Lucia, et al.
Published: (2021-01-01) -
Pioglitazone Alleviates Cardiac Fibrosis and Inhibits Endothelial to Mesenchymal Transition Induced by Pressure Overload
by: Wen-Ying Wei, et al.
Published: (2017-12-01) -
Cardiac fibrosis as a determinant of ventricular tachyarrhythmias
by: Norishige Morita, MD, PhD, et al.
Published: (2014-12-01) -
Endostatin in fibrosis and as a potential candidate of anti-fibrotic therapy
by: Zequn Zhang, et al.
Published: (2021-01-01) -
T Cells in Fibrosis and Fibrotic Diseases
by: Mengjuan Zhang, et al.
Published: (2020-06-01)